Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780700 · ClinicalTrials.gov registry record · Phase 2
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02780700 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 1 participants.
The verdict
NCT02780700, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines of standard treatment
Interventions
- DRUG Capecitabine
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-07-05 |
| Est. Completion | 2016-09-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780700
The ClinicalTrials.gov registry entry for NCT02780700 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT02780700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780700 about?
NCT02780700 is a clinical study titled "Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]". The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines of standard treatment
What is the current status of trial NCT02780700?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-07-05. Estimated completion is 2016-09-09.
What interventions are being tested in trial NCT02780700?
The interventions under investigation include: Capecitabine (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT02780700?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.